World-first mRNA melanoma vaccine: what the phase 3 results mean

If you have been treated for melanoma — or if someone you care about has — there is a piece of news this week worth pausing on.

An Australian-led phase 3 trial of a personalised mRNA cancer vaccine called intismeran has found a 42% reduction in the risk of melanoma recurring when the vaccine is added to pembrolizumab immunotherapy. Results were presented at the European Society for Medical Oncology (ESMO) Congress and published in the New England Journal of Medicine. The trial ran at 157 sites globally and enrolled 1,137 patients with stage II–IV melanoma who had already had surgery to remove their cancer.

Australia didn’t just participate. It led. Melanoma Institute Australia, Peter MacCallum Cancer Centre, Westmead Hospital, Princess Alexandra Hospital, and One Clinical Research in Western Australia were all involved. The steering committee was chaired by Professor Georgina Long, Melanoma Institute Australia’s medical director — one of the 2024 Australians of the Year. Professor Long called the results “better than she expected.” She used the phrase “foundational shift.”

That phrase carries weight. Here is what it means, and what it doesn’t.

What the vaccine actually does

The concept is easier to understand once you know that melanoma’s Achilles’ heel is its genetic mutations. Tumours are full of them — and many are unique to each person’s cancer.

This is how the vaccine works: a biopsy of the removed tumour is compared with the patient’s healthy cells. The top 34 mutations that exist only in the cancer — not in the rest of the body — are identified and ranked. Those 34 are then encoded as messenger RNA, the same technology used in COVID-19 vaccines, and administered as a personalised injection. The immune system reads the mRNA, recognises the “wanted poster” for the cancer cells, and is primed to attack them if they come back.

Professor Long described it as the immune system getting a “wanted poster” for the cancer. The analogy is apt: without the vaccine, the immune system may not recognise returning cancer cells as foreign. With it, it has a specific target.

This is added to pembrolizumab — an immunotherapy already used in melanoma treatment that helps the immune system recognise cancer more broadly. The 42% reduction in recurrence was for that combination versus pembrolizumab alone.

Both-and: what these results do and don’t resolve

There is genuine reason to regard this as landmark research. A 42% relative reduction in recurrence in a disease where Australia has the highest incidence in the world — one diagnosis every 30 minutes and one death every six hours — is a meaningful number. The phase 3 design, the publication in the NEJM, and the scale of the trial give this a credibility ceiling that phase 1 or 2 results wouldn’t carry.

And the personalisability matters. Most cancer treatments are designed around an average patient. This vaccine is literally different for each person who receives it. That is a conceptual shift.

What the results don’t resolve:

Long-term data is limited. The observation period is approximately two years. Whether the protection holds beyond that, and what the survival benefit is over a longer horizon, remains unknown. Dr Jessamy Tiffen of the Centenary Institute made this point explicitly, and it is worth holding.

Not everyone responds. A significant proportion of patients in the trial did not show an initial response to the vaccine. The reasons for this are not yet fully understood. Research into predictors of response is ongoing.

It is not available. Regulatory review — including by the TGA — must follow the NEJM publication. This process typically takes two to several years, and cost and access decisions follow regulatory approval. People who have been treated for melanoma cannot access this treatment now.

It does not prevent melanoma. This vaccine is for people who have already had melanoma removed. Sun protection, avoiding solariums, and regular skin checks by a GP or dermatologist remain the primary prevention strategies. Those have not changed.

Professor Alex Menzies of Melanoma Institute Australia noted the approach could eventually extend to other cancers — particularly those where current immunotherapies work poorly. That is worth watching over the coming years.

2 cents: what this means for your terrain this week

If you have been treated for melanoma, the honest answer is: nothing changes for you this week. No new treatment is available. Your follow-up with your oncologist or GP continues as planned.

What is reasonable is to bring this to that conversation. Ask your oncologist whether you would be a candidate for a trial if one becomes accessible. Understand your staging. Know that this research exists and is real.

If you are a GP: patients who have read this news will have questions. The key messages — 42% relative reduction in recurrence, phase 3, not yet available, not preventative — are enough to anchor a brief conversation. Melanoma Institute Australia is the right referral destination for patients who want to understand the research in depth.

If this is the first time you are hearing about melanoma rates in Australia: about 16,000 Australians are diagnosed each year. Australia has the highest incidence globally. Regular skin checks with a GP — particularly if you are fair-skinned, have a family history, or have significant sun exposure history — remain worthwhile.

Verdict: yes — worth knowing about.

---

Sources cited

1. Australia at the heart of ‘transformational’ melanoma cancer vaccine breakthrough — ABC News, 23 Oct 2026
2. Melanoma Institute Australia — melanoma facts and statistics